Caffeoylquinic Acid-Rich Extract of Aster glehni F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPAR δ and Adiponectin in ApoE KO Mice.
This study was performed to investigate the effects of A. glehni on nonalcoholic fatty liver disease (NAFLD) in atherosclerotic condition, by determining the levels of biomarkers related to lipid metabolism and inflammation in serum, liver, and adipose tissue. Body and abdominal adipose tissue weights and serum triglyceride level decreased in all groups treated with A. glehni. Serum adiponectin concentration and protein levels of peroxisome proliferator-activated receptor δ, 5' adenosine monophosphate-activated protein kinase, acetyl-CoA carboxylase, superoxide dismutase, and PPARγ coactivator 1-alpha in liver tissues increased in the groups treated with A. glehni. Conversely, protein levels of ATP citrate lyase, fatty acid synthase, tumor necrosis factor α, and 3-hydroxy-3-methylglutaryl-CoA reductase and the concentrations of interleukin 6 and reactive oxygen species decreased upon A. glehni. Triglyceride concentration in the liver was lower in mice treated with A. glehni than in control mice. Lipid accumulation in HepG2 and 3T3-L1 cells decreased upon A. glehni treatment; this effect was suppressed in the presence of the PPARδ antagonist, GSK0660. Our findings suggest that A. glehni extracts may ameliorate NAFLD through regulation of PPARδ, adiponectin, and the related subgenes. PMID: 29201040 [PubMed]
Hirokazu Takahashi, Kazuhiko Kotani, Kenichi Tanaka, Yuichiro Egucih, Keizo Anzai
Journal of Magnetic Resonance Imaging, EarlyView.
Conclusions: Non-obese patients present a substantial proportion of pediatric NAFLD cases. Significant abnormal lipid concentrations were found in non-obese and abdominal obesity was important risk factor for non-obese NAFLD. PMID: 30304905 [PubMed - as supplied by publisher]
In this systematic review and meta-analysis, we found that bariatric surgery leads to biopsy-confirmed resolution of NAFLD and significant reductions of NAS. However, 12% of patients developed new or worsened NAFLD following the procedure.
ConclusionThese findings suggest that GSO has a beneficial effect on NAFLD through the suppression of lipogenesis and stimulation of fatty acid degradation pathway.
FRIDAY, Oct. 12, 2018 -- For patients with nonalcoholic fatty liver disease (NAFLD), modest alcohol consumption is associated with a reduction in all-cause mortality, while drinking 1.5 or more drinks per day may increase mortality, according to a...
This article is protected by copyright. All rights reserved. PMID: 30312023 [PubMed - as supplied by publisher]
Authors: Raschi E, Mazzotti A, Poluzzi E, De Ponti F, Marchesini G Abstract INTRODUCTION: Pharmacotherapy used to treat type 2 diabetes mellitus (T2DM) is facing a paradigm shift in clinical practice with recent cardiovascular (CV) outcome trials having a substantial impact on drug prescription with treatment having a more tailored approach. In patients with T2DM, the issue of chronic liver disease is multifaceted. However, a clinical evidence is emerging on the beneficial effect of antidiabetic medications on nonalcoholic fatty liver disease (NAFLD). Areas covered: The authors provide a synopsis on the current and...